SAB Biotherapeutics, Inc. SABS
Set alert
3.30 USD -0.05 -1.49%
At close
3.22 -0.08 -2.42%
Pre-market · Nov 3, 6:11 AM ET
3.28 Day range 3.40
2.44 52-week range 5.15
- YTD
- -11.76%
- 1 year
- +1.54%
- Open
- 3.35
- Prev close
- 3.35
- Mkt cap
- 300.26M
- Vol
- 487.81K
- Avg vol
- 539.15K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.28
- High
- 3.40
- Forward P/E
- -1.56
- Beta
- 0.64
- Short ratio
- 1.22
- Inst. own
- 34.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.29
- 200-d avg
- 3.35
- 1y target
- 12.40
3M chart
Signals (22)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
Newest 20 of 22.
Analyst view
Consensus: none
Price target (mean) 12.40 +275.8% upside
Now 3.30
- Target (low)
- 6.00
- Target (mean)
- 12.40
- Target (high)
- 25.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.21 | -1.21 – -1.21 | -6.39 | +81.1% | 120.00K | -60.7% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 333.33K | -64.7% | 0 |
| Current year | -3.64 | -3.64 – -3.64 | -6.77 | +46.2% | 1.34M | -39.9% | 1 |
| Next year | -5.01 | -5.01 – -5.01 | -3.64 | -37.6% | 800.00K | -40.5% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Oct 9, 2024 | Craig-Hallum | Initiated | — | Buy |
| Sep 12, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Sep 9, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 28, 2024 | Oppenheimer | Initiated | — | Outperform |
| Aug 12, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 7, 2024 | Brookline Capital | Initiated | — | Buy |
| May 21, 2024 | Chardan Capital | Maintained | Buy | Buy |
| May 21, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 16, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Apr 2, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |